SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing intense downward pressure and widespread investor skepticism following a lackluster earnings report and broader concerns over AI capital expenditure. The community is deeply polarized, with bears pointing to bearish technical breakdowns and executive controversies, while bulls are actively debating whether current levels represent a long-term accumulation opportunity or a value trap.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing heavy volatility as investors weigh strong earnings and AI demand against broader concerns regarding rising capital expenditures and macroeconomic pressures. The community remains deeply divided, with some traders viewing the current pullback as a manipulation-driven buying opportunity while others warn of a broader correction in overvalued semiconductor stocks.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to China's recent inclusion of the company on its export control list, a move aimed at tightening access to critical dual-use materials. The community remains divided, with some viewing the geopolitical pressure as a long-term validation of the firm's strategic importance for U.S. defense and supply chain independence, while others express frustration over recent stock volatility and the ongoing pressure from short sellers.

Wolfspeed, Inc. is an innovator of wide bandgap semiconductors, focused on silicon carbide and gallium nitride (GaN) materials and devices for power and radiofrequency (RF) applications. Its product families include silicon carbide and GaN materials, power devices and RF devices, and its products are targeted for various applications such as electric vehicles, fast charging, 5G, renewable energy and storage, and aerospace and defense. The company was founded by Calvin H. Carter Jr., John W. Palmour, F. Neal Hunter, Eric Hunter, and John Edmond in 1987 and is headquartered in Durham, NC.

Wolfspeed Inc - Ordinary Shares (New)

Wolfspeed Inc

Wolfspeed is seeing intense market volatility and heavy short interest as investors react to a recent collaboration with GE Aerospace and a strategic pivot toward data center solutions. Community discussion remains polarized, with some traders betting on a significant short squeeze due to high short float, while others express frustration over lingering concerns regarding production capacity, dilution, and the company's past financial restructuring.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X ETF

Direxion Daily TSLA Bull 2X Shares

Investors are closely watching TSLL as Tesla's price volatility sparks intense debate over whether to "buy the fear" or brace for further downside, particularly with ongoing discussions around technical support levels and the risks of a reverse split. The community remains deeply polarized, with some bulls emphasizing long-term autonomy and robotics potential while skeptics warn against the punishing effects of leverage decay during high-volatility swings.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing heightened volatility and community debate as investors navigate a heated proxy battle with the former CEO and track progress on Project Matador. While the stock has seen significant price swings, discussion is primarily focused on the impending announcement of an anchor tenant and the potential for a major re-rating once the company achieves its infrastructure development milestones.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing heightened volatility and intense social media debate as investors weigh the anticipated Starship test flight against significant concerns regarding upcoming share lockup expirations and lofty valuations. The community remains deeply polarized, with bulls pointing to the potential of a successful launch to drive momentum, while bears argue that fundamental headwinds and looming supply increases suggest further downward pressure.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is currently facing significant selling pressure as investors digest a large stock offering while navigating broader sector-wide volatility linked to the recent SpaceX market debut. Despite the pullback, the community remains divided, with some investors highlighting the company's strong revenue growth and long-term satellite data moat, while others express frustration over management's decision to dilute shares during a turbulent time for space stocks.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently attracting significant attention as community members debate whether heavy trading activity and elevated short interest point toward a potential short squeeze or aggressive institutional accumulation. Investors are closely monitoring management's optimistic outlook on second-half performance alongside ongoing discussions regarding a potential strategic partnership, while sentiment remains divided between those betting on fundamental undervaluation and others concerned about debt levels and executive leadership.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors digest the negative CHMP opinion on its lead drug arimoclomol, triggering a sharp sell-off despite the company's plan to request a formal re-examination. While the community is debating whether the rejection stems from regulatory hurdles or presentation issues, many long-term holders are highlighting the company's U.S. revenue, cash position, and ongoing pipeline assets as reasons to potentially buy the dip.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results...

Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?

Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris Board of...

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity...

Xeris Announces Updates to Its Board of Directors

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its Board of Directors appointed John Shannon to Chair of the Board...

Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS

Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States...

Xeris Biopharma Announces Private Exchange of Convertible Notes

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements...

Xeris Biopharma (XERS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma Reports First Quarter 2026 Financial Results

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of...

Beth Hecht Sells 16,667 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) insider Beth Hecht sold 16,667 shares of the firm's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $6.23, for a total value of $103,835.41. Following the sale, the insider directly owned 1,193,173...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards another losing week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$8.35
Prev Close	$8.41
Open	$8.49
Dividend Yield	0.00%
50-Day Moving Average	$7.21
Beta	1.20
Avg. Volume	2.06M
PE Ratio	128.40

52-Week High	$10.08
52-Week Low	$4.87
Market Capitalization	$1.45B
EPS (Annual)	$0.0032
Price to Book	111.54
Revenue Per Employee	$670,908.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

XERSXeris Biopharma Holdings Inc

Latest XERS News